Moderators:

• Joel Cardenas-Goicoechea, MD, Mount Sinai School of Medicone, New York, NY
• Marian Williams-Brown, MD, MMS, FACOG, University of Texas at Austin, Austin, TX

Description: Featured posters represent the highest ranked among all poster submissions. During this session, featured poster presenters will each present their abstract in 3 minute talks.

Location: Hawaii Convention Center 313AB

ABSTRACT 59

Presentation has been withdrawn at author’s request.

ABSTRACT 60

Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer

C.B. Williams, K.A. Williams, A.K. Krie, N.L. Flier, S. Schwingler, R. Coppock, R. Lockhorst, G. Middendorff, B. Leyland-Jones, N. Dey, P. De, L.A. Rojas-Espaillat and D.C. Starks
Avera Cancer Institute, Sioux Falls, SD, USA

ABSTRACT 61
Mechanisms of SWI/SNF dysfunction in the immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type

J.R. Patibandla1, E. Van Oudenhove2, P. Jelinic2 and D.A. Levine1,2
1New York University School of Medicine, New York, NY, USA, 2NYU Langone Health, New York, NY, USA

ABSTRACT 62
Homologous recombination DNA repair defects in copy-number high serous-like endometrial cancers

C.W. Ashley, A.D.C. Paula, R. Kumar, D. Mandelker, X. Pei, N. Riaz, J. Reis-Filho and B. Weigelt
Memorial Sloan Kettering Cancer Center, New York, NY, USA

ABSTRACT 63
PD-1/PD-L1 expression in BRCA1/2 mutated ovarian cancers

C.A. Penn1, J. Lester1, K. Bohrer2, C. Moon2, J. Yearley2, B.Y. Karlan1 and C. Walsh1
1Cedars-Sinai Medical Center, Los Angeles, CA, USA, 2Merck & Company, Inc., Whitehouse Station, NJ, USA

ABSTRACT 64
Clinical outcomes of patients with POLE-mutated endometrioid endometrial cancer

M. Stasenko1, I.U. Tunnage2, C.W. Ashley1, M. Rubinstein1, J.J. Mueller1, M.M. Leitao Jr.1, V. Makker1, C.F. Friedman1, R.A. Soslow1, D.M. Hyman1, A.J. Latham1, B. Weigelt1, C.A. Aghajanian1, N.R. Abu-Rustum1 and K.A. Cadoo1
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Georgetown/Washington Hospital Center, Washington, DC, USA

ABSTRACT 65
Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies

R.C. Arend1, C.M. Castro2, U.A. Matulonis3, E. Hamilton4, C.C. Gunderson5, K.S.S. Lybarger6, M. Kagey7, C. Sirard7 and M.J. Birrer1
1University of Alabama at Birmingham, Birmingham, AL, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Dana-Farber Cancer Institute, Boston, MA, USA, 4Sarah Cannon Research Instititute Tennessee Oncology, Nashville, TN, USA, 5The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 6University of Missouri - Kansas City, Kansas City, MO, USA, 7Leap Therapeutics, Inc., Cambridge, MA, USA

ABSTRACT 66
Presentation has been withdrawn at author’s request.

ABSTRACT 67
The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in uterine serous carcinoma overexpressing HER2

G. Yadav1,2, S. Lopez1, C. Han1, G. Altwerger1, G. Menderes1, S. Bellone1, A. Bianchi1, E.S. Ratner1, P.E. Schwartz1 and A.D. Santin1
1Yale University School of Medicine, New Haven, CT, USA, 2Baylor College of Medicine, Houston, TX, USA

ABSTRACT 68
Therapeutic AXL inhibition of tumor and tumor microenvironment stromal cells improves response to chemotherapy in ovarian cancer

M.M. Mullen1, E. Lomonosova1, H. Beck-Noia1, D. Wilke1, L. Guo1, A.R. Hagemann1, L.M. Kuroki1, C.K. McCourt2, P.H. Thaker1, D.G. Mutch1, M.A. Powell1 and K.C. Fuh1
1Washington University School of Medicine in St. Louis, St. Louis, MO, USA, 2Women & Infants Hospital, Brown University, Providence, RI, USA

ABSTRACT 69
The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.

C. Han1, G. Altwerger1, G. Menderes1, S. Bellone1, A. Bianchi1, G. Yadav1, S. Lopez1,2, A. Manzano1, E.S. Ratner1, M. Azodi1, B. Litkouhi1, D.A. Silasi1, G.S. Huang1, P.E. Schwartz1 and A.D. Santin1
1Yale University School of Medicine, New Haven, CT, USA, 2Magna Graecia University, Catanzaro, Italy

ABSTRACT 70
Dasatinib, paclitaxel and carboplatin in women with advanced-stage and recurrent endometrial cancer: A pilot clinical and translational study

R.L. Coleman1, W. Hu1, P.T. Soliman1, A.M. Nick2, P.T. Ramirez1, S.N. Westin1, Z. Zu1, K.M. Schmeler1, D.C. Bodurka1, L.A. Meyer1 and A.K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2St. Thomas Medical Partners, Nashville, TN, USA

ABSTRACT 71
Surgery induces broad changes in clinically relevant genes regulating immune and metabolic responses in murine epithelial ovarian cancer

P.C. Mayor1, S.N. Akers1, P.J. Frederick1, S.B. Lele1, E. Cortes Gomez2, J. Wang2, S. Lynam2, J.E. Mark2, K. Starbuck2, E. Zsiros2, K.L. Singel2, K. Odunsi1, J. Ohm2
and B.H. Segal1
1Roswell Park Cancer Institute, Buffalo, NY, USA, 2Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

ABSTRACT 72
The lack of benefit of chemotherapy for stage I uterine leiomyosarcoma patients: A retrospective analysis of 890 patients

M.T. Richardson1, J.K. Chan2, D.S. Kapp1, A.K. Mann3 and C.I. Liao4
1Stanford University School of Medicine, Stanford, CA, USA, 2California Pacific Medical Center, San Francisco, CA, USA, 3Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA, 4Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan

ABSTRACT 73
Profiling the metabolomic composition of the ovarian cancer secretome and ovarian cancer-induced metabolomic changes in mesothelial cells

I.M. Lazo1, A. Mukherjee1, H. Kenny1, S. Fan2, I. Blaženović2, O. Fiehn2 and E. Lengyel3
1The University of Chicago Medicine, Chicago, IL, USA, 2University of California, Davis, Davis, CA, USA, 3University of Chicago, Chicago, IL, USA

ABSTRACT 74
Epigenetics tells the mole story: DNA methylation identifies complete moles destined to develop into gestational trophoblastic neoplasia

J.D. St. Laurent1,2, L. Lin3, I. Maestá4, N.S. Horowitz5,6,7, R.S. Berkowitz5,8,9 and K.M. Elias2,5,8,10
1Massachusetts General Hospital, Boston, MA, USA, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 3University of Sao Paulo, São Paulo, Brazil, 4Sao Paulo State University, Botucatu, São Paulo, Brazil, 5New England Trophoblastic Disease Center, Boston, MA, USA, 6Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA, 7Brigham and Women’s Hospital, Boston, MA, USA, 8Dana-Farber Cancer Institute, Boston, MA, USA, 9Brigham and Women’s Hospital/Harvard University, Boston, MA, USA, 10Harvard Medical School, Boston, MA, USA